Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Shanghai Tyligand Bio to Acquire China Rights to Cancer Drug from Context

publication date: Mar 24, 2020

Tyligand Bioscience, a Shanghai small molecule company, acquired exclusive China rights to onapristone ER from Context therapeutics in return for designing and optimizing a novel manufacturing process for the candidate. Onapristone extended release is a clinical stage treatment aimed at hormone driven cancers. Tyligand will be responsible for developing the candidate in China and will pay royalties on any revenues to Context. Currently, Context, a Philadelphia company, is conducting a Phase II trial of the molecule in patients with progesterone receptor positive (PR+) ovarian and endometrial cancers. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital